Cargando…

Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection

BACKGROUND: Staphylococcus aureus (S. aureus) causes a wide range of infectious diseases in human and animals. The emergence of antibiotic-resistant strains demands novel strategies for prophylactic vaccine development. In this study, live attenuated S. enterica subsp. enterica serotype Typhimurium...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chen, Zhang, Bao-zhong, Lin, Qiubin, Deng, Jian, Yu, Bin, Arya, Smriti, Yuen, Kwok-Yung, Huang, Jian-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921394/
https://www.ncbi.nlm.nih.gov/pubmed/29699491
http://dx.doi.org/10.1186/s12879-018-3104-y
_version_ 1783318001081122816
author Xu, Chen
Zhang, Bao-zhong
Lin, Qiubin
Deng, Jian
Yu, Bin
Arya, Smriti
Yuen, Kwok-Yung
Huang, Jian-Dong
author_facet Xu, Chen
Zhang, Bao-zhong
Lin, Qiubin
Deng, Jian
Yu, Bin
Arya, Smriti
Yuen, Kwok-Yung
Huang, Jian-Dong
author_sort Xu, Chen
collection PubMed
description BACKGROUND: Staphylococcus aureus (S. aureus) causes a wide range of infectious diseases in human and animals. The emergence of antibiotic-resistant strains demands novel strategies for prophylactic vaccine development. In this study, live attenuated S. enterica subsp. enterica serotype Typhimurium (S. Typhimurium) vaccine against S. aureus infection was developed, in which Salmonella Pathogenesis Island-1 Type 3 Secretion System (SPI-1 T3SS) was employed to deliver SaEsxA and SaEsxB, two of ESAT-6-like (Early Secreted Antigenic Target-6) virulence factors of S. aureus. METHODS: Antigens SaEsxA and SaEsxB were fused with the N-terminal secretion and translocation domain of SPI-1 effector SipA. And cytosolic delivery of Staphylococcal antigens into macrophages was examined by western blot. BALB/c mice were orally immunized with S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines. Antigen-specific humoral and Th1/Th17 immune responses were examined by ELISA and ELISPOT assays 7–9 days after the 2nd booster. For ELISPOT assays, the statistical significance was determined by Student’s t test. The vaccine efficacy was evaluated by lethal challenge with two S. aureus clinical isolates Newman strain and USA 300 strain. Statistical significance was determined by Log rank (Mantel-Cox) analysis. And a P value of < 0.05 was considered statistically significant. RESULTS: Oral administration of S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines induced antigen-specific humoral and Th1/Th17 immune responses, which increased the survival rate for vaccinated mice when challenged with S. aureus strains. CONCLUSIONS: The newly developed S. Typhimurium-based vaccines delivering SaEsxA and SaEsxB by SPI-1 T3SS could confer protection against S. aureus infection. This study provides evidence that translocation of foreign antigens via Salmonella SPI-1 T3SS into the cytosol of antigen presenting cells (APCs) could induce potent immune responses against pathogens. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-018-3104-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5921394
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59213942018-05-01 Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection Xu, Chen Zhang, Bao-zhong Lin, Qiubin Deng, Jian Yu, Bin Arya, Smriti Yuen, Kwok-Yung Huang, Jian-Dong BMC Infect Dis Research Article BACKGROUND: Staphylococcus aureus (S. aureus) causes a wide range of infectious diseases in human and animals. The emergence of antibiotic-resistant strains demands novel strategies for prophylactic vaccine development. In this study, live attenuated S. enterica subsp. enterica serotype Typhimurium (S. Typhimurium) vaccine against S. aureus infection was developed, in which Salmonella Pathogenesis Island-1 Type 3 Secretion System (SPI-1 T3SS) was employed to deliver SaEsxA and SaEsxB, two of ESAT-6-like (Early Secreted Antigenic Target-6) virulence factors of S. aureus. METHODS: Antigens SaEsxA and SaEsxB were fused with the N-terminal secretion and translocation domain of SPI-1 effector SipA. And cytosolic delivery of Staphylococcal antigens into macrophages was examined by western blot. BALB/c mice were orally immunized with S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines. Antigen-specific humoral and Th1/Th17 immune responses were examined by ELISA and ELISPOT assays 7–9 days after the 2nd booster. For ELISPOT assays, the statistical significance was determined by Student’s t test. The vaccine efficacy was evaluated by lethal challenge with two S. aureus clinical isolates Newman strain and USA 300 strain. Statistical significance was determined by Log rank (Mantel-Cox) analysis. And a P value of < 0.05 was considered statistically significant. RESULTS: Oral administration of S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines induced antigen-specific humoral and Th1/Th17 immune responses, which increased the survival rate for vaccinated mice when challenged with S. aureus strains. CONCLUSIONS: The newly developed S. Typhimurium-based vaccines delivering SaEsxA and SaEsxB by SPI-1 T3SS could confer protection against S. aureus infection. This study provides evidence that translocation of foreign antigens via Salmonella SPI-1 T3SS into the cytosol of antigen presenting cells (APCs) could induce potent immune responses against pathogens. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-018-3104-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-25 /pmc/articles/PMC5921394/ /pubmed/29699491 http://dx.doi.org/10.1186/s12879-018-3104-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Xu, Chen
Zhang, Bao-zhong
Lin, Qiubin
Deng, Jian
Yu, Bin
Arya, Smriti
Yuen, Kwok-Yung
Huang, Jian-Dong
Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
title Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
title_full Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
title_fullStr Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
title_full_unstemmed Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
title_short Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
title_sort live attenuated salmonella typhimurium vaccines delivering saesxa and saesxb via type iii secretion system confer protection against staphylococcus aureus infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921394/
https://www.ncbi.nlm.nih.gov/pubmed/29699491
http://dx.doi.org/10.1186/s12879-018-3104-y
work_keys_str_mv AT xuchen liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection
AT zhangbaozhong liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection
AT linqiubin liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection
AT dengjian liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection
AT yubin liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection
AT aryasmriti liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection
AT yuenkwokyung liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection
AT huangjiandong liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection